India, Sept. 26 -- A total investment of Rs 5,210.74 crore has been made under the Production-Linked Incentive (PLI) scheme for bulk drugs as of June 2026, with 39 projects for manufacturing 28 active pharmaceutical ingredients/key starting materials (APIs/KSMs) being commissioned, according to an official statement on Friday. The government had in 2020 approved the PLI Scheme for bulk drugs, with a total financial outlay of Rs 6,940 crore.

The government has made wide-ranging efforts to increase investment in the pharmaceutical sector for enhancing manufacturing capabilities, to prevent disruption in supply of critical APIs used to make critical drugs and promote medical device industry under the PLI scheme, the Ministry of Chemicals an...